KRAS and cancer: Several inhibitors that bind to a region close to switch II were identified, such as ARS-853 [20], tetrahydropyridopyrimidines [21], MRTX849 [22], and AMG510 [23]., However, their covalent nature restricts the usage to only G12C mutations and cancers, with other KRAS mutations such as G12D, G12V, and Q61H lacking the reactive cysteine to be an effective target for these covalent KRAS inhibitors [24].